ReShape Lifesciences granted key international patent in Australia

ReShape Lifesciences (RSLS) announced that the Company was granted a key international patent from the Australian Patent Office for its Diabetes Neuromodulation technology. Patent number 2019252920, entitled, “Simultaneous Multi-Site Vagus Nerve Neuromodulation For Improved Glycemic Control System And Methods,” will provide protection until April 12, 2039. The Diabetes Neuromodulation system leverages its proprietary vagus nerve block technology platform, along with vagus nerve stimulation, to treat Type 2 diabetes, a prominent disorder linked with obesity.